Morgan Stanley Myriad Genetics Inc Transaction History
Morgan Stanley
- $1.35 Trillion
- Q3 2024
A detailed history of Morgan Stanley transactions in Myriad Genetics Inc stock. As of the latest transaction made, Morgan Stanley holds 880,987 shares of MYGN stock, worth $14.7 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
880,987
Previous 1,372,637
35.82%
Holding current value
$14.7 Million
Previous $33.6 Million
28.18%
% of portfolio
0.0%
Previous 0.0%
Shares
19 transactions
Others Institutions Holding MYGN
# of Institutions
254Shares Held
90.9MCall Options Held
100KPut Options Held
34K-
Black Rock Inc. New York, NY15.2MShares$253 Million0.01% of portfolio
-
Vanguard Group Inc Valley Forge, PA10.3MShares$172 Million0.01% of portfolio
-
Wellington Management Group LLP Boston, MA6.72MShares$112 Million0.03% of portfolio
-
Israel Englander Millennium Management LLC | New York, Ny5.18MShares$86.4 Million0.07% of portfolio
-
State Street Corp Boston, MA4.7MShares$78.5 Million0.01% of portfolio
About MYRIAD GENETICS INC
- Ticker MYGN
- Exchange NASDAQ
- Sector Healthcare
- Industry Diagnostics & Research
- Shares Outstandng 80,634,800
- Market Cap $1.35B
- Description
- Myriad Genetics, Inc., a genetic testing and precision medicine company, develops and commercializes genetic tests in the United States and internationally. The company offers molecular diagnostic tests for use in oncology, and women's and mental health applications. It provides MyRisk Hereditary Cancer Test, a DNA sequencing test for assessing ...